Introduction
The American Geriatric Society updated their Beers Criteria in 2012, 1 
and the European Screening Tool for Older Person's Prescriptions (STOPP)/Screening Tool to Alert Doctors to Right Treatment (START) criteria 2008
2 and 2015, 3 and the Japan Geriatrics Society (JGS) 2005 criteria for the medical treatment and safety of the elderly have also been revised. The updated guidelines have been improved using a comprehensive, systematic review and evidence grading. The JGS guidelines contain a chapter for traditional Chinese medicine (TCM; traditional medicines in East Asian countries, such as China, Japan, Korea, Taiwan, Vietnam and Singapore, and the China town district of most major cities), because it is widely used for elderly patients and is sometimes covered by national medical insurance in Japan. The title of the chapter is Kampo medicine and traditional Asian medicine, but we record these as TCM in our present review, because TCM is now the global standard academic term meaning traditional medicines in East Asian countries. To update the guidelines, the systematic review of TCM for geriatrics is required.
Furthermore, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system is now widely used in the development of clinical guidelines. 4 It involves rating the quality of evidence (QoE) and grading the strength of recommendations (RS), 4 and is now used by more than 90 organizations and journals including the World Health Organization, Cochrane library and UptoDate. However, despite its widely adopted use and assessment in clinical trials, is not evaluated by the GRADE system.
In the present study, we systematically reviewed TCM for geriatrics, and prepared the list to update the guideline.
Methods
The complete method is summarized in a flowchart (Fig. 1) . The principal steps in systematic review of TCM and quality assessment of studies according to the modified GRADE system were: 1 To evaluate TCM studies not addressed in the JGS 2005 guideline for the medical treatment and safety of the elderly. 2 Grade the strength and quality of each study based on its QoE according to the modified GRADE system. 3 Convene an interdisciplinary panel of 20 experts in geriatric care and pharmacotherapy, including two experts in TCM, who will apply a modified Delphi method to the systematic review and grading in order to reach a consensus on the updated 2015 JGS Criteria. Two research questions (RQ) were set: 1 Can TCM improve the symptoms of diseases in the elderly? 2 What adverse reactions occur in the elderly after TCM use?
Literature search
Literature from 1 January 1972 to 22 November 2013 was searched to identify published systematic reviews that were relevant to the project. Search terms included aged, elder, senior, older, aging, geriatric, geriatric assessment, East Asian Traditional Medicine, Kampo Medicine, Chinese Traditional Medicine, Chinese herbal drugs, herb-drug interaction, herbal medicine, medicinal plant, plant components, plant extracts, phytotherapy, phytomedicine, Kampo, Oriental medicine, Japanese traditional medicine, Korean medicine, acupuncture and moxibustion. Terms were searched alone and in combination. The search criteria included the involvement of human participants aged 65 years or older, and publication in English or Japanese. Data sources for the initial search included PubMed and the Cochrane Library.
Quality assessment of studies
The JGS used the slightly modified GRADE system that was recommended in the Medical Information Network Distribution Service 2014. 5 The minor differences between these versions of GRADE are not relevant to the present report. However, there are few clinical studies with a high QoE for adverse reactions to TCM, and a welldesigned large-scale randomized control study to prove an adverse reaction to TCM has proved unrealistic. Therefore, the guideline committee decided that although the START list would be prepared according to the modified GRADE system, the STOPP list would be based on alert documents from the Ministry of Health, Labor and Welfare in Japan. These contain many types of evidence, including single case reports, case series, historical knowledge about TCM and pharmacological findings.
The initial search identified 503 citations of traditional medicines. A TCM expert who was also a geriatrician (K I ) reviewed all of the abstracts and selected 57 for secondary review. For START, only evidence from randomized controlled trials (RCT) or higher were selected. Studies not concerned with drug intervention (acupuncture or moxibustion), studies of traditional medicines other than TCM (for example, Ayurveda), citations for which the full manuscripts could not be obtained (for example, because they were published in a domestic Chinese journal), medical interventions that could not be used (such as herbal extract injection practiced in China) and studies having strong publication bias were excluded. Seven recent reports from a manual search were added later. Therefore, structured abstracts were prepared for 64 studies. Two TCM experts, the authors of the present report, evaluated the QoE and RS of each outcome according to the modified GRADE system.
Preparing the START and STOPP lists
Two TCM experts prepared the initial draft version of START and STOPP. TCM prescriptions listed in START were defined as prescriptions from high to low QoE and with a strong or weak RS, and that were covered by national medical insurance in Japan. STOPP list items were selected based on a range of evidence, including single case reports, case series, historical knowledge about TCM and pharmacological findings. TCM prescriptions containing herbs with well-known adverse effects were listed in STOPP, even if evidence for these were lacking. The combined lists formed the STOPP for Japanese. TCM prescriptions possibly available to geriatric patients and having a high to low QoE, but that were not available in Japan, were excluded.
Expert panel discussion
The panel consisted of eight professors of geriatric medicine, a senior hospital pharmacist, eight senior academic primary care physicians, two experts in TCM and geriatrics, and the head of the Japan National Hospital for Geriatrics and Gerontology. In-person panel meetings were held four times a year for 3 years, and additional discussions were held electronically. The TCM chapter, lists of START and STOPP criteria with RQ, and their related commentary and instructions were reviewed.
Results
To address RQ1, 37 RCTand meta-analyses were selected. These suggested that TCM might improve the symptoms of diseases of older adults, at least with respect to dementia and mild cognitive impairment (cognitive function, 6, 7 behavioral and psychological symptoms of dementia, post-stroke symptoms [activities of daily living [13] [14] [15] [16] ], depression, 17 aspiration pneumonia [18] [19] [20] and constipation 21 ), chronic obstructive pulmonary disease, 22, 23 hyperlipidemia, [24] [25] [26] [27] [28] [29] foot ulcer as a result of diabetes mellitus, 30 osteoporosis, 31 post-abdominal surgery complications, 32 chronic constipation, 33,34 the prevention 35 and treatment 36, 37 of influenza, angina pectoris, 38 and hypertension. 39 A total of 18 TCM prescriptions and herbs that were identified to have high, moderate or low QoE for older adults, of which Yigan San, Banxia houpu Tang, Dajianzhong Tang, Buzhongyiqi Tang and Ma Zi Ren Wan are covered by Japanese national insurance, were therefore listed in START (Table 1) . Unfortunately, the guideline panel could not make consensus about RS of TCM. Therefore, here we report only the results of systemic review and QoE of some TCM listed on START.
QoE determinations in START
The efficacy of Yigan San was reviewed by a meta-analysis of four RCT, which showed that it could relieve behavioral and psychological symptoms of dementia. [8] [9] [10] [11] [12] However, all of these studies were open labeled, and thus had an increased risk of bias, which is a limitation in the GRADE system. The QoE of Yigan San for behavioral and psychological symptoms of dementia was evaluated as moderate.
Banxia Houpu Tang was assessed in three RCT, [18] [19] [20] which found that it could improve the swallowing and cough reflex in cerebrovascular disease patients. 18, 19 All three trials were limited by their open label design, and two lacked sample size estimations. 18, 19 A more convincing finding was that this medication could prevent aspiration pneumonia (risk ratio 0.5). 20 The QoE of this TCM was considered to be moderate.
Dajianzhong Tang was included in two RCT, one of which was open label, 21 and the other blinded using a placebo. 32 The latter presented a high QoE, and showed improved bowel movement after gastric surgery, which reflects the typical use of this medicine in Japan for preventing ileus after abdominal surgery.
Buzhongyiqi Tang was assessed in two small, open labeled RCT, the findings of which suggested that it improved systemic inflammation and nutritional status in elderly patients with COPD and reduced systemic inflammation. 22, 23 Although the small cohort size and open label design of these trails resulted in a low QoE, Buzhongyiqi Tang was included because it represents a unique therapeutic strategy to improve nutritional status and control chronic inflammation, something that is lacking in Western medicine.
Ma Zi Ren Wan (hemp seed pill) was evaluated as a purgative in a very well-designed double-blind RCT. 33 The participants of the Cheng study were aged 18-65 years; however, our research question was as follows: "Can TCM improve disease symptoms in the elderly?" Therefore, it was necessary to consider indirectness in the GRADE system. No other factors that decrease the QoE were found in the present study. Hence, this medication was given a moderate QoE in our review. A more detailed review of its clinical efficacy and use is given in the Appendix.
A total of 11 prescriptions were composed and used in China. There was evidence for the effectiveness of two herbs, tea and dried garlic, but they were excluded from START by a team of experts because they are not drugs, although they have both been used as herbs for a long time. These 13 prescriptions and herbs, and their associated QoEm is listed in Table 2 .
In order to address RQ2, TCM prescriptions containing five herbs with known adverse reactions were listed in STOPP ( Table 3 ). As discussed above, their associated QoE was very low, and was based on many different sources. In Japan, herbs are listed in the pharmacopeia, and adverse reactions are reported and published by the Pharmaceutical and Medical Devices Agency, 40 as is all STOPP Pharmaceutical and Medical Devices Agency drug-related information. 41 
Discussion
In the present article, TCM for geriatrics was systematically reviewed, and its QoE were assessed according to the modified GRADE system. Overall, TCM might improve the symptoms of diseases of older adults. A total of 18 TCM prescriptions and herbs were identified to have high, moderate or low QoE. At the end of this 3-year study, a secret vote was taken by panel members without a conflict of interest (16 of 20 members who were not TCM experts), 62.5% of them supported the list of START and STOPP made by the results of this study, but this was below the 80% required to change the guidelines. Therefore, STARTand STOPP of TCM were not included in the general list of STOPP for Japanese, and were instead included as an independent chapter. In the chapter, the START list was included in the list of Kampo medicine suggested to be available for older adults, and the STOPP list was included as the list of herbs that we should pay attention to for older adults. As an important point, herbs listed in the STOPP are surely used in TCM, because they each have a drug effect. For example, Fructus Gardeniae has anti-inflammatory, sedative, hemostatic and choleretic effects. Therefore, it is used to treat bleeding, dysmenorrhea, jaundice and so on.
The most serious reason that the members could not accept the list of START and STOPP was the luck of evidence of TCM compared with modern medicine. Next, it was partly as a result of the lack of a questionnaire survey for patients or other relevant groups aimed at evaluating their opinions of TCM. Although this might have helped us determine the RS of TCM, it would have been too costly and time-consuming. Despite this, the chapter content, QoE and RS all took into account over 200 public comments from other medical societies, experts, general physicians and patients. However, committee members had very different types of expertise and views for TCM, which led to a failure to build consensus in RS. Although Japan has its own traditional medicine, Kampo (TCM modified in Japanese style), its attitude to traditional Antiwei (安体威) Antiwei increased the recovery rate by 17% (P < 0.001), and reduced the severity of illness measured by the median symptom score by 50% (P < 0.001) in both influenza-like and influenzaconfirmed populations, compared with the placebo.
None Moderate 36
Lianhuaqingwen capsule (LHC) (连花清瘟胶囊)
There were no significant overall differences between LHC treated and Oseltamivir treated patients in the median duration of illness (LHC 69 h vs. Oseltamivir 85 h P > 0.05) or the median duration of viral shedding (LHC 103 h vs Oseltamivir 96 h, P > 0.05). However, it was notable that LHC significantly reduced the severity of illness and the duration of symptoms including fever, cough, sore throat, and fatigue (P < 0.05).
No drug related serious adverse events occurred during the study.
medicine is ambivalent. Many herbs are listed in the Japanese pharmacopeia, their use is covered by national medical insurance and more than 80% of physicians prescribe them. Nevertheless, Kampo has only very limited coverage in medical education, and receives very little public research funding. Furthermore, official guidelines cover only approximately 11% of traditional medicines. 42 One possible reason why committee members could not understand the utility of Kampo medicine relates to medical education in Japan. The Japanese Ministry of Education, Culture, Science, Sports and Technology revised Japanese medical education to include Kampo as an essential part of the curriculum in 2001, 43 and it has therefore been incorporated into medical education in all 80 Japanese medical schools since 2007. 44 Therefore, not all committee members had been educated regarding Kampo medicine. Furthermore, training and instruction in the use of Kampo medicine has never been included in the attainment targets of the Ministry of Health, Labor and Welfare in Japan. This lack of uniformity in medical education was ultimately reflected in the panel's decision.
In Germany, basic information about traditional medicine is included in the undergraduate medical curriculum, and systematic training in traditional medicine is provided at a postgraduate level. 45 Over 9000 doctors belong to DÄGfa (the German Doctors' Society for Acupuncture), which has contributed to the education of traditional medicine including acupuncture, moxibustion, herbal medicine, TCM and traditional Japanese medicine. 46 Core members of DÄGfa have carried out large-scale clinical studies of traditional medicine over the past 10 years, providing evidence for its efficacy and safety. China also incorporated TCM into the curriculum of medical schools, and doctors from Western countries have been educated in 47 Traditional medicine is now widely taught worldwide, and we suggest that Japan should also include Kampo medicine in undergraduate and postgraduate teaching. Japan's policy sharply contrasts with that of other countries. Asian countries each have their own traditional medicines and some, especially China, India and South Korea, consider their traditional medicines to be a key component of managing the medical burden in a super-high aging era, and are funded and regulated accordingly. Japan should follow this example.
Our attempt at a systematic review to update the JGS guidelines represents the first assessment of TCM using the GRADE system. We found that the GRADE system could be used to evaluate TCM, at least partially, and might be useful in other TCM trials. We suggest that these guidelines should be modified for each country in which TCM is used or, in the future, by an international organization, such as the World Health Organization.
Limitations
The first limitation was the inclusion of only Japanese panel members, which made it more difficult to assess the RS of TCM in other countries as, although it has a common origin, its application has regional variations. Therefore, at present, TCM guidelines need to be tailored to the country in which they are used. Second, although we searched for studies from Korea using the search term "Korean medicine," none were found. This was For prolonged administration lasting years check the colon by endoscopic examination every 2 or 3 years. unexpected, as Korea has a long history of traditional medicine and has developed effective prescriptions, such as Daesiho, which has anti-inflammatory effects in cerebral infarction. 48 A manual search of this literature was not possible. It is hoped that Korean researchers will prepare their own, country-specific guidelines.
Conclusion
Systematic review and the evaluation with the modified GRADE system were carried out for TCM in older adults. TCM might improve the symptoms of diseases of older adults. Based on the results of the present study, the JGS did not include TCM in STOPP for Japanese, although five TCM and five herbs were included in the TCM chapter. Further training and research will be required for TCM.
